We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran
Read MoreHide Full Article
Sanofi (SNY - Free Report) and partner Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the FDA has lifted clinical hold placed on all ongoing studies of its hemophilia candidate fitusiran.
In September, Alnylam stopped dosing in all ongoing studies of fitusiran, a RNA interference (RNAi) therapeutic, following a death event in an open-label extension (OLE) phase II study. The patient was suffering from hemophilia A and died after developing a blood clot inside cerebral venous sinus (thrombotic event).
Alnylam and Sanofi are taking additional risk mitigation measures for fitusiran studies as there have been concerns about risks around safety in hemophilia disease. Protocol amendments and other updated clinical materials for these studies have been approved by the FDA. Dosing in fitusiran studies including OLE and phase III ATLAS studies is expected to resume around end of the year.
A look at Alnylam’s share price movement shows that the stock has massively outperformed the industry year to date. The stock has surged 235.4% compared with the industry’s growth of 3.4%.
Meanwhile, Sanofi’s shares have gained 6.7% so far this year, comparing unfavorably with the industry’s gain of 17.1%. The company carries a Zacks Rank #4 (Sell).
Please note that Alnylam and Sanofi have an agreement to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe while Sanofi will exclusively market the candidate, on approval, in rest of the world.
Emergent BioSolutions’ earnings estimates have moved up by 11.5% for 2018 over the last 30 days. Share price of the company has risen 42.5% year to date.
While XOMA shares have skyrocketed 655.5% year to date, its 2018 loss estimates have narrowed almost 20% over the past 60 days.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran
Sanofi (SNY - Free Report) and partner Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the FDA has lifted clinical hold placed on all ongoing studies of its hemophilia candidate fitusiran.
In September, Alnylam stopped dosing in all ongoing studies of fitusiran, a RNA interference (RNAi) therapeutic, following a death event in an open-label extension (OLE) phase II study. The patient was suffering from hemophilia A and died after developing a blood clot inside cerebral venous sinus (thrombotic event).
Alnylam and Sanofi are taking additional risk mitigation measures for fitusiran studies as there have been concerns about risks around safety in hemophilia disease. Protocol amendments and other updated clinical materials for these studies have been approved by the FDA. Dosing in fitusiran studies including OLE and phase III ATLAS studies is expected to resume around end of the year.
A look at Alnylam’s share price movement shows that the stock has massively outperformed the industry year to date. The stock has surged 235.4% compared with the industry’s growth of 3.4%.
Meanwhile, Sanofi’s shares have gained 6.7% so far this year, comparing unfavorably with the industry’s gain of 17.1%. The company carries a Zacks Rank #4 (Sell).
Please note that Alnylam and Sanofi have an agreement to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe while Sanofi will exclusively market the candidate, on approval, in rest of the world.
Some better-ranked stocks in the biotech/genetics sector include Emergent BioSolutions Inc. (EBS - Free Report) and XOMA Corporation (XOMA - Free Report) , both with a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent BioSolutions’ earnings estimates have moved up by 11.5% for 2018 over the last 30 days. Share price of the company has risen 42.5% year to date.
While XOMA shares have skyrocketed 655.5% year to date, its 2018 loss estimates have narrowed almost 20% over the past 60 days.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>